Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Historically, much of the focus on monoamine oxidases and their substrates has been in the area of depression and the monoamine neurotransmitters serotonin (5-hydroxytryptamine), noradrenaline, and to a lesser extent, dopamine. With both forms of monoamine oxidase (A and B), the production of hydrogen peroxide as a byproduct of the reaction between the monoamine oxidases and their monoamine substrates has also implicated monoamine oxidase-sensitive events in intrinsic cell death pathways, particularly those centered on oxidative stress and peroxyradical-mediated mechanisms. Consequently, and perhaps not unexpectedly, the inhibition of monoamine oxidase has been considered as adjunctive therapy in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease, both of which involve a significant oxidative stress component. Yet the literature also provides ambiguities; indeed, not all of the functions of monoamine oxidases are dependent on catalytic activity nor can they all be ascribed to expression levels of the monoamine oxidase protein per se. Recent reports strongly suggest that the functions of monoamine oxidases also rely on posttranslational modifications, epigenetic influences, interactions with other proteins, the cell phenotype and its localization to specific subcellular compartments. These recent developments certainly complicate the issue, yet they need to be duly considered when implicating monoamine oxidases and their inhibitors in both in vitro and in vivo pathological contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230 · cited 1×
“In contrast, the degradation of serotonin, noradrenaline and dopamine (and any associated cellular dysfunction) by MAO-A has been historically associated primarily with the neurobiology, and treatment, of depression [44, 47, 48] rather than any neurodegenerative phenotype.”
Background
Cited by
13 reasons why the brain is susceptible to oxidative stress
Cobley, J. N., Fiorello, M. L., & Bailey, D. M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.008 · Cited by 1,215
The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress
Juárez Olguín, H., Calderón Guzmán, D., Hernández García, E., & Barragán Mejía, G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9730467 · Cited by 462
Dopamine in Parkinson's disease
Latif, S., Jahangeer, M., Maknoon Razia, D., Ashiq, M., Ghaffar, A., Akram, M., El Allam, A., Bouyahya, A., Garipova, L., Ali Shariati, M., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.08.009 · Cited by 340
Engel, D. F., de Oliveira, J., Lopes, J. B., Santos, D. B., Moreira, E. L. G., Farina, M., Rodrigues, A. L. S., de Souza Brocardo, P., & de Bem, A. F. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.029 · Cited by 44
A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease
Lee, S. Y., Song, M.-Y., Kim, D., Park, C., Park, D. K., Kim, D. G., Yoo, J. S., & Kim, Y. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01653 · Cited by 32
“Several mechanisms have been proposed to account for involvement of MAO in AD pathologysuchascognitivedysfunction via destroyingcholinergic neurons and the formation of Aß aggregation or NFTs (Thomas, 2000; Huang et al., 2012; Mousseau and Baker, 2012; Cai, 2014; Quartey et al., 2018).”
Background
Metadata
- Authors
- D. Mousseau, D., & B. Baker, G.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-10-01
- Volume
- 12
- Issue
- 20
- Pages
- 2163-2176
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2322941916
- Cited by
- 36
- References
- 1
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.